{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Uterine Cervical Neoplasms","Solid Tumor","Carcinoma","Cervical Cancer","Melanoma","Mesothelioma","Cutaneous Squamous Cell Carcinoma","Oropharynx Cancer","Carcinoma, Squamous Cell","Squamous Cell Carcinoma of Head and Neck","Microsatellite Stable Colorectal Cancer","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Melanoma (Skin)","Mesothelioma, Malignant","Renal Cell Carcinoma","Oropharyngeal Neoplasms"],"disease":["Uterine Cervical Neoplasms","Solid Tumor","Carcinoma","Cervical Cancer","Melanoma","Mesothelioma","Cutaneous Squamous Cell Carcinoma","Oropharynx Cancer","Carcinoma, Squamous Cell","Squamous Cell Carcinoma Of Head And Neck","Microsatellite Stable Colorectal Cancer","Melanoma (skin)","Mesothelioma, Malignant","Renal Cell Carcinoma","Hpv Positive Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2332523"],"location":["Canada","South Korea","United States"],"study_start_month":["6"],"keyword":["Oropharyngeal","Pembrolizumab","HPV cancer","CRC","Oncolytic Virus","MSS-CRC","Intratumoral injection","Renal Cell","Skin cancer"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors","description":"To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).","dates":{"creation":"2020-06-15"},"accession":"2332523","cross_references":{"ClinicalTrials___gov":["NCT04301011"]}}